Treatment of T315I mutation: Indian perspective

The management of chronic myeloid leukemia (CML) has evolved significantly with the introduction of tyrosine kinase inhibitors. However, the emergence of resistance, particularly the T315I mutation, poses a formidable challenge. This review examines current treatment options for T315I mutation, focusing on their efficacy and availability, with a specific emphasis on the Indian perspective. While drugs such as ponatinib, omacetaxine mepesuccinate, asciminib, and PF-114 have shown promise against T315I mutation, their limited availability and high cost present significant barriers in the Indian context. Moreover, poor tolerability and adverse effects with existing treatments further complicate the treatment landscape. Efforts to improve access to novel therapies and explore alternative treatment modalities are essential to address this challenge and improve outcomes for patients with T315I-mutant CML and philadelphia-positive acute lymphoblastic leukemia.